Entyvio (Wave 1) | LaunchTrends | US | 2014
Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market following launch. The report evaluates physicians’ current awareness and familiarity with Entyvio, the advantages and disadvantages compared to currently available therapies, and the current and anticipated usage of the drug; as well as the drug’s promotional activity.
Related Market Assessment Reports
Report
Type 2 Diabetes – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
GLP-1 receptor agonists – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent graft rejection and maintain the new kidney’s functionality, patients…
